Bowen’s Disease



Bowen’s disease (BD) is an intraepidermal squamous cell carcinoma (SCC) with a tendency for progressive growth and low invasive risk, characterized by slowly growing, erythematous plaque with an irregular border, surface scaling and crusting. The risk of progression to invasive SCC is 3–5 % for extragenital lesions and 10 % for genital lesions. BD is very common in the Caucasian population with an incidence of 14 per 100,000 in some populations. The peak age group for BD is the seventh decade. The ratio of Bowen’s disease is approximately equal between males and females. BD is more commonly found on the head and neck of men and on the lower limbs and cheeks of women. BD is usually a solitary lesion, but in 10–20 % of patients, it occurs at multiple sites.


Intraepidermal Squamous Cell Carcinoma Extragenital Lesions Surface Scaling Superficial Basal Cell Carcinoma Methyl Aminolevulinate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





5-Aminolevulinic acid


Bowen’s disease


Human papillomavirus


Methyl aminolevulinate


Photodynamic therapy


Squamous cell carcinoma


  1. Dawe SA, Salisbury JR, Higgins E. Two cases of Bowen’s disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel. Clin Exp Dermatol. 2005;30:712–3.CrossRefGoogle Scholar
  2. Patel MJ, Stockfleth E. Does progression from actinic keratosis and Bowen’s disease end with treatment: diclofenac 3% gel, an old drug in a new environment? Br J Dermatol. 2007;156 Suppl 3:53–6.CrossRefGoogle Scholar
  3. Smith KJ, Germain M, Skelton H. Bowen’s disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg. 2001a;27:143–6.PubMedGoogle Scholar
  4. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen’s disease) in renal transplant patients treated with 5% imiquimod and 5% fluorouracil therapy. Dermatol Surg. 2001b;27:561–4.PubMedGoogle Scholar

Further Reading

  1. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56(1):125–43.CrossRefGoogle Scholar
  2. Chung YL, Lee JD, Bang D, et al. Treatment of Bowen’s disease with a specially designed radioactive skin patch. Eur J Nucl Med. 2000;27(7):842–6.CrossRefGoogle Scholar
  3. Clavel CE, Huu VP, Durlach AP, et al. Mucosal oncogenic human papillomaviruses and extragenital Bowen disease. Cancer. 1999;86(2):282–7.CrossRefGoogle Scholar
  4. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen’s disease. Br Assoc Dermatol Br J Dermatol. 1999;141(4):633–41.CrossRefGoogle Scholar
  5. Cox NH, Eedy DJ, Morton CA. Guidelines for management of Bowen’s disease: 2006 update. Br J Dermatol. 2007;156(1):11–21.CrossRefGoogle Scholar
  6. Dave R, Monk B, Mahaffey P. Treatment of Bowen’s disease with carbon dioxide laser. Laser Surg Med. 2003;32:335.CrossRefGoogle Scholar
  7. Derancourt C, Mougin C, Chopard-Lallier M, et al. Oncogenic human papillomaviruses in extra-genital Bowen disease revealed by in situ hybridization. Ann Dermatol Venerol. 2001;128:715–8.Google Scholar
  8. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen’s disease in transplant recipients. Transplantation. 2004;77(1):115–21.CrossRefGoogle Scholar
  9. Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen’s disease) in immunocompromised patients. J Am Acad Dermatol. 2008;59(1):68–71.CrossRefGoogle Scholar
  10. Dupree MT, Kiteley RA, Weismantle K, Panos R, Johnstone PA. Radiation therapy for Bowen’s disease: lessons for lesions of the lower extremity. J Am Acad Dermatol. 2001;45(3):401–4.CrossRefGoogle Scholar
  11. Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol. 1988;119(2):231–40.CrossRefGoogle Scholar
  12. Kao GF. Carcinoma arising in Bowen’s disease. Arch Dermatol. 1986;122(10):1124–6.CrossRefGoogle Scholar
  13. Kossard S, Rosen R. Cutaneous Bowen’s disease. An analysis of 1001 cases according to age, sex, and site. J Am Acad Dermatol. 1992;27(3):406–10.CrossRefGoogle Scholar
  14. Kovács A, Yonemoto K, Katsuoka K, Nishiyama S, Harhai I. Bowen’s disease: statistical study of a 10 year period. J Dermatol. 1996;23(4):267–74.CrossRefGoogle Scholar
  15. Lallas A, Argenziano G, Zendri E, et al. Update on non-melanoma skin cancer and the value of dermoscopy in its diagnosis and treatment monitoring. Expert Rev Anticancer Ther. 2013;13:541–58.CrossRefGoogle Scholar
  16. Landthaler M, Haina D, Brunner R, Waidelich W, Braun-Falco O. Laser therapy of bowenoid papulosis and Bowen’s disease. J Dermatol Surg Oncol. 1986;12(12):1253–7.CrossRefGoogle Scholar
  17. Lee MM, Wick MM. Bowen’s disease. CA Cancer J Clin. 1990;40:237–42.CrossRefGoogle Scholar
  18. Lee JD, Park KK, Lee MG, et al. Radionuclide therapy of skin cancers and Bowen’s disease using a specially designed skin patch. J Nucl Med. 1997;38(5):697–702.PubMedGoogle Scholar
  19. Leibovitch I, Huilgol S, Seva D, et al. Cutaneous squamous cell carcinoma in situ (Bowen’s disease): treatment with Mohs’ micrographic surgery. J Am Acad Dermatol. 2005;52:997–1002.CrossRefGoogle Scholar
  20. Morton CA, Whitehurst C, Moore J, et al. Photodynamic therapy vs cryotherapy in the treatment of Bowen’s disease. Clin Exp Dermatol. 1996;21:79.Google Scholar
  21. Neubert T, Lehmann P. Bowen’s disease – a review of newer treatment options. Ther Clin Risk Manag. 2008;4(5):1085–95.PubMedPubMedCentralGoogle Scholar
  22. Plaza de Lanza M, Ralfs I, Dawber R. Cryosurgery for Bowen’s disease of the skin. Br J Dermatol. 1980;103:14.Google Scholar
  23. Prinz BM, Hafner J, Dummer E, et al. Treatment of Bowen’s disease with imiquimod 5% cream in transplant recipients. Transplantation. 2004;77:790–1.CrossRefGoogle Scholar
  24. Quinn AG, Perkins W. Rook’s textbook of dermatology. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Non-melanoma skin cancer and other epidermal skin tumors. 8th ed. London: Wiley; 2010. p. 2644–6.Google Scholar
  25. Reizner GT, Chuang TY, Elpern DJ, Stone JL, Farmer ER. Bowen’s disease (squamous cell carcinoma in situ) in Kauai. Hawaii. A population-based incidence report. J Am Acad Dermatol. 1994;31(4):596–600.CrossRefGoogle Scholar
  26. Sarmiento JM, Wolff BG, Burgart LJ, et al. Perianal Bowen’s disease: associated tumors, human papillomavirus, surgery, and other controversies. Dis Colon Rectum. 1997;40:912–8.CrossRefGoogle Scholar
  27. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol. 1989;8(2):99–104.CrossRefGoogle Scholar
  28. Stevens DM, Kopf AW, Gladstein A, Bart RS. Treatment of Bowen’s disease with grenz rays. Int J Dermatol. 1977;16(5):329–39.CrossRefGoogle Scholar
  29. Szeimies RM, Abels C, Fritsch C, et al. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. J Invest Dermatol. 1995;105(5):672–7.CrossRefGoogle Scholar
  30. Tantikun N. Treatment of Bowen’s disease of the digit with carbon dioxide laser. J Am Acad Dermatol. 2000;43(6):1080–3.CrossRefGoogle Scholar
  31. Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm Venereol. 1988;68(3):236–9.PubMedGoogle Scholar
  32. Turpin IM. Radionuclide therapy of skin cancers and Bowen’s disease using a specially designed skin patch. Plast Reconstr Surg. 1999;103:1333.Google Scholar
  33. Welch ML, Grabski WJ, McCollough ML, et al. 5-Fluorouracil iontophoretic therapy for Bowen’s disease. J Am Acad Dermatol. 1997;36:956–8.CrossRefGoogle Scholar
  34. Wojnarowska F, Cooper SM. Dermatology. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Anogenital (Non-venereal) Disease. Edinburgh: Mosby; 2003. p. 1106.Google Scholar
  35. Wolf Jr JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40(11):709–13.CrossRefGoogle Scholar
  36. Yerebakan O, Ermis O, Yilmaz E, Basaran E. Treatment of arsenical keratosis and Bowen’s disease with acitretin. Int J Dermatol. 2002;41(2):84–7.CrossRefGoogle Scholar
  37. Zygogianni A, Kouvaris J, Tolia M, Kyrgias G, Beli I, Kantzou I, et al. The potential role of radiation therapy in Bowen’s disease: a review of the current literature. Rev Recent Clin Trials. 2011;7(1):42–6Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Dermatovenerology, Dermatooncology UnitUniversity Hospital Centre “Sestre Milosrdnice”ZagrebCroatia
  2. 2.Referral Centre for Melanoma of the Ministry of Health of the Republic of CroatiaZagrebCroatia
  3. 3.School of Dental MedicineUniversity of ZagrebZagrebCroatia
  4. 4.President of the Croatian Dermatovenereological Society of the Croatian Medical AssociationZagrebCroatia

Personalised recommendations